Abivax Turns Away Suitors as Lead Drug Starts Covid-19 Tests
Abivax, the French biotech embarking on tests of its lead experimental medicine for Covid-19, has turned away several suitors in recent months.
MEDEOR, Truffle Capital's new BioMedTech Fund, qualified by institutional investors through the Tibi committee
Medeor is among the 24 new funds qualified by the committee of institutional investors set up following the Tibi report.
Investors Search for Promising Covid Cures
The race to develop vaccines and treatments to build immunity to the novel coronavirus ...
Abivax Stock Soars as French Regulator Approves Testing of a Drug to Treat Covid-19
The French biotech company Abivax announced Thursday that it had received clearance from French regulators to begin a 1,000 patient trial ...
Abivax to evaluate anti-inflammatory effects of ABX464 in large-scale COVID-19 trial
Abivax SA has rejected an acquisition offer in order to pursue a phase IIb/III trial of its lead anti-inflammatory drug ABX464 ...
Pharnext, a Truffle Capital creation, fights Covid-19
How to find existing effective drugs, against coronavirus
Bloomberg : Diaccurate Scientists show how HIV disables Immune System
Truffle Capital Raises € 250m Fund to Launch Life Science Startups
The French VC firm Truffle Capital has closed a fund worth € 250m with a mission to nurture companies specializing in medical devices
Consortium with Nestlé Waters, PepsiCo and Suntory Beverage & Food
Impressive 12-month Efficacy and Safety Data from ABX464
FDA approval to launch a clinical feasibility study in the United States
Inclusion of the first patient in Abivax's Phase 2b (ABX464-103) clinical trial for the treatment of hemorrhagic rectocolitis
The main evaluation criterion is the reduction of Mayo's score to 8 weeks.
Abivax treats first rheumatoid arthritis patient in Phase 2a clinical trial
The clinical trial was approved in the following four European countries: France, Poland, Czech Republic and Hungary ...
1st PET bottles from 100% biorecycled plastic waste
FDA grants Fast Track designation for the development of PTX3003 in the treatment of patients with Charcot-Marie-Tooth disease type 1a
Positive interim results from the first part of the PIVOTAL study
Positive interim results from the first part of the PIVOTAL study (10 patients) ...